While alopecia areata has been recognized as an auto-immune disorder, androgenic Alopecia appears to be the most common form of male and female hair shedding which affects 50% of men by the age 50 and 50% of women by the age 60. Advances in biology of hair loss at molecular level provided better understanding of causes of hair loss and a new approach to its treatment. This approach involves inhibition of 5-alpha reductase, the enzyme which reduces testosterone to its more active form, dihydro testosterone, one of major breakthroughs in developing anti aging hair loss serum.
Dihydrotestosterone is currently thought to be the most potent androgen affecting the human hair growth cycle, with adverse effects in male pattern hair loss. A recent study suggests role of interleukin-17 in androgenic alopecia and inhibition of this inflammatory maker as a potential treatment for hair loss.
Hair loss in women: Given the protective effect of estrogen and progesterone, there are female hair thinning, which are due to hormonal imbalance and increased DHT level as well. DHT blockers such as Follicle Treatment, an anti aging hair loss serum, enjoying natural ingredients stimulates hair growth by blocking androgen receptors and enzyme 5-alpha reductase, which in turn reduces DHT production in both men and women.
Androgenic alopecia appear to be less severe and less frequent in females due to less expression, about as half, of 5-alpha-reductase and androgen receptors in females compare to males counterpart. In addition, aromatase activity in female hair follicles promotes conversion of testosterone to estradiol rather than DHT.
Blockers of dihydrotestosterone use different mechanisms to reduce dihydrotestosterone, among them are:
Blocking the alpha receptors in the hair follicles
Inhibition of the enzyme 5 alpha reductase, responsible for conversion of testosterone into DHT
Reducing the substances that can produce the enzyme 5 alpha reductase like cholesterol
In susceptible hair follicles, dihydrotestosterone binds to the androgen receptor, and the hormone-receptor complex activates the genes responsible for the gradual transformation of large terminal follicles to miniaturized follicles. Both young women and young men with androgenic alopecia have higher levels of 5-alpha reductase and androgen receptor in frontal hair follicles compared to occipital follicles. At the same time, young women have much higher levels of cytochrome p-450 aromatase in frontal follicles than men who have minimal aromatase, and women have even higher aromatase levels in occipital follicles.
Twice more common than general population is the incidence rate of atopic dermatitis in alopecia areata patients, who are also at 43% increased risk of new onset atopic dermatitis, a large population-based study of two cohorts of 40,255 subjects has found.While alopecia areata has been perceived an auto-immune disorder, its association with atopy directs us to come up with treatments which also address atopic disease.
One study suggests increased expression of CD4 cells, CCR6+ CD4 cells, which are essential for CD8 cells priming, in alopecia areata patients to provide rationale for role of atopy in the pathology of the disease. A 48-week double blind multi-center study on efficacy of dupilumab, further delivered results indicating 30% improvement in SALT score, substantianting role of atopy in pathogenesis of alopecia areata. Dupilumab is a monoclonal antibody which binds alpha subunit of IL-4.
Follicle Treatment, our anti aging hair loss serum, a natural DHT blocker is an anti aging solution to male and female pattern hair loss. This anti aging hair loss product is based on latest medical research on causes of hair loss in women and men. It is now known that dihydrotestosterone (DHT), a by-product of testosterone, is the detrimental agent that may be a hair loss cause. Simply put, under certain conditions DHT “strangles” hair follicles>
Most recent hair loss research has proven that DHT is responsible for the progressive shrinking of the hair follicle. While this process is the primary cause of hair loss in women, there are several other factors that contribute to further deterioration of the hair follicle.
Oxidative stress, reactive oxygen species and free radical generation may account for hair thinning and loss to a significant degree. Nutrient deficient hair follicles, poor circulation of the scalp, over active sebaceous glands, and clogged or harshly treated hair follicles are among these factors.
Growth factors contribute to transition from follicular stem cells to hair follicle cells by supporting angiogenesis and making provisions to cells depleted in oxygen and nutrients through stress and aging, promoting telogen to anagen phase switch within hair follicles. Among a plethora of growth factos, IGF-1, insulin-like growth factor-1, TGF-β, transforming growth factor-beta, EGF, epithelial growth factor, PDGF, platelet-derived growth factor, VEGF, vascular endothelial growth factor have been more researched and more data is available on their profiles.
While growth factors are implicated in cell signaling and cell proliferation, they also exert an anti inflammatory perfomance by releasing IL-1 antagonist receptor, sTNF, soluble TNF receptor, IL-4, IL-10 and IL-13, which is another aspect of cascade of events imparting to hair loss.
Hair loss, particularly androgenic alopecia (AGA) and alopecia areata (AA), represents a major dermatological concern affecting both men and women globally. With advancements in molecular biology and immunology, the underlying pathogenesis of these conditions has become increasingly understood. This discussion synthesizes current findings on the roles of dihydrotestosterone (DHT), 5-alpha reductase, interleukin-17, and hormonal dysregulation, while exploring the therapeutic significance of natural DHT blockers, anti-inflammatory cytokine modulators, and lifestyle modifications.
While alopecia areata is widely acknowledged as an autoimmune-mediated condition, androgenic alopecia remains the most prevalent form of non-scarring alopecia, affecting up to 50% of men by age 50 and 50% of women by age 60. The condition is characterized by a progressive miniaturization of hair follicles, primarily due to the effects of DHT, a potent androgen metabolite. Recent developments in molecular endocrinology have paved the way for novel, targeted interventions that go beyond cosmetic concealment to address the root biochemical causes.
Central to the pathophysiology of AGA is the enzyme 5-alpha reductase, which catalyzes the conversion of testosterone into DHT, a hormone implicated in follicular regression. Elevated DHT levels lead to a progressive shrinkage of terminal hair follicles, especially in the frontal and vertex regions of the scalp. Both male and female individuals with AGA exhibit upregulated expression of 5-alpha reductase and androgen receptors in susceptible areas, although female hair loss tends to be less severe due to:
These sex-specific differences in enzymatic and hormonal profiles account for the distinct patterns of hair loss observed between men and women.
In females, estrogen and progesterone exert a protective effect on hair follicles. However, hormonal imbalances, particularly during menopause or endocrine disorders, can result in elevated levels of DHT and subsequent follicular degeneration. The use of natural DHT-blocking agents, such as those found in anti-aging hair loss serums, is gaining traction. These formulations often aim to:
Such approaches are being marketed as integrative solutions, combining cosmetic benefits with endocrine modulation.
Recent immunological studies have uncovered the role of pro-inflammatory cytokines, particularly interleukin-17 (IL-17), in both alopecia areata and potentially androgenic alopecia. IL-17 is known to:
The implication of IL-17 inhibitors (such as monoclonal antibodies) in clinical trials presents a promising therapeutic avenue. Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, has shown 30% improvement in SALT scores in patients with AA, further validating the inflammatory–immune axis in alopecia pathogenesis.
Epidemiological data suggest a significantly higher incidence of atopic dermatitis among individuals with alopecia areata, with some studies indicating a 43% increased risk of developing atopic conditions post-AA diagnosis. This association may be explained by:
These insights reinforce the need for comprehensive treatment models that not only address hair regrowth but also modulate systemic immune responses.
Chronic oxidative stress, lipid peroxidation, and free radical accumulation have been implicated in premature hair follicle aging. Lifestyle interventions that enhance antioxidant capacity, improve circulatory health, and support scalp detoxification are becoming integral to long-term hair health strategies. In this context, anti-aging hair loss serums now incorporate:
These multi-targeted formulations such as anti aging hair loss serum aim to restore the telogen–anagen transition, enhance microcirculation, and rejuvenate follicular stem cell environments.
The evolving understanding of hair loss etiology — from hormonal to immune and environmental factors — has catalyzed a paradigm shift in treatment approaches. By integrating molecular endocrinology, immunomodulation, and anti-aging medicine, clinicians and researchers are now better equipped to offer personalized, evidence-based interventions for both male and female pattern hair loss. Anti aging hair loss serum has been developed in conjunction with these advances in enhancing metabolic processes which lead to hair regeneration.
Future research should continue to investigate the interplay of systemic inflammation, hormonal regulation, and follicular microenvironments, as well as explore the therapeutic potential of biologics, natural enzyme inhibitors, and regenerative compounds in managing chronic alopecia.
